SLXN news

Silexion Therapeutics Corp announced the first patient has been successfully dosed in a global Phase 2/3 trial of the RNAi therapy SIL204 for locally advanced pancreatic cancer, marking a key operational milestone.

Silexion reported that its SIL204 utilizes native serum lipoproteins for cellular delivery, validating a mechanism for systemic administration in KRAS-driven cancers without artificial nanoparticles.

Silexion Therapeutics Corp filed an exhibit marked as a slide deck in the SEC filing. It includes a standard forward-looking statement risk section indicating the company is a development-stage enterprise with limited operating history and has never generated revenue.

Silexion Therapeutics completed a 1-for-10 reverse share split to maintain compliance with Nasdaq Capital Market minimum bid price listing requirements. The consolidation reduces outstanding shares from approximately 4.07 million to 407,471 issued shares while proportionally increasing par value.

Silexion Therapeutics completed a 1-for-10 reverse share split effective May 28, 2026, to maintain Nasdaq listing compliance and support its clinical development of SIL-204 for KRAS-driven cancers. The move aims to achieve a higher stock price, reduce volatility, and broaden investor access ahead of…